Relationship Between Multidrug-Resistant Enterobacterales and Obesity in Older Adults

References

• Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1–8.
   Google Scholar
• Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic. Int J Epidemiol. 2020;49(3):810–823. doi:10.1093/ije/dyz27332016289
   PubMed Web of Science ®Google Scholar
• Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381:2440–2450. doi:10.1056/NEJMsa190930131851800
   PubMed Web of Science ®Google Scholar
• Falagas M, Kompoti M. Obesity and infection. Lancet Infect Dis. 2006;6:438–446. doi:10.1016/S1473-3099(06)70523-016790384
   PubMed Web of Science ®Google Scholar
• Huttunen R, Syrjanen J. Obesity and the risk and outcome of infection. Int J Obes. 2013;37:333–340. doi:10.1038/ijo.2012.62
   PubMed Web of Science ®Google Scholar
• Bertakis KD, Azari R. Obesity and the use of health care services. Obes Res. 2005;13:372–379. doi:10.1038/oby.2005.4915800296
   PubMedGoogle Scholar
• Huttunen R, Laine J, Lumio J, Vuento R, Syrjänen J. Obesity and smoking are factors associated with poor prognosis in patients with bacteraemia. BMC Infect Dis. 2007;7:13. doi:10.1186/1471-2334-7-1317349033
   PubMed Web of Science ®Google Scholar
• Bochicchio GV, Joshi M, Bochicchio K, Tracy K, Scalea TM. A time‐dependent analysis of intensive care unit pneumonia in trauma patients. J Trauma. 2004;56:296–301. doi:10.1097/01.TA.0000109857.22312.DF14960971
   PubMedGoogle Scholar
• Falagas ME, Athanasoulia AP, Peppas G, Karageorgopoulos DE. Effect of body mass index on the outcome of infections: a systematic review. Obes Rev. 2009;10:280–289.19243518
   PubMed Web of Science ®Google Scholar
• Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22:970–976. doi:10.1002/pds.346123733599
   PubMed Web of Science ®Google Scholar
• Tucker CE, Lockwood AM, Nguyen NH. Antibiotic dosing in obesity: the search for optimum dosing strategies. Clin Obes. 2014;4:287–295. doi:10.1111/cob.1207625826157
   PubMedGoogle Scholar
• Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25:634–649. doi:10.1097/QCO.0b013e328359a4c123041773
   PubMed Web of Science ®Google Scholar
• Narayanan N, Adams CD, Kubiak DW, et al. Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient. Infect Drug Resist. 2019;12:877–891. doi:10.2147/IDR.S19626431114267
   PubMed Web of Science ®Google Scholar
• Sarmiento MRA, de Paula TO, Borges FM, et al. Obesity, xenobiotic intake and antimicrobial-resistance genes in the human gastrointestinal tract: a comparative study of eutrophic, overweight and obese individuals. Genes. 2019;10:349. doi:10.3390/genes10050349
   Web of Science ®Google Scholar
• Roe JL, Fuentes JM, Mullins ME. Underdosing of common antibiotics for obese patients in the ED. Am J Emerg Med. 2012;30:1212–1214. doi:10.1016/j.ajem.2011.05.02722169576
   PubMed Web of Science ®Google Scholar
• Roberts JA, Kruger P, Paterson DL, Lipman J. Antibiotic resistance--what’s dosing got to do with it? Crit Care Med. 2008;36:2433–2440. doi:10.1097/CCM.0b013e318180fe6218596628
   PubMed Web of Science ®Google Scholar
• Garg A, Garg J, Kumar S, Bhattacharya A, Agarwal S, Upadhyay GC. Molecular epidemiology & therapeutic options of carbapenem-resistant Gram-negative bacteria. Indian J Med Res. 2019;149:285–289. doi:10.4103/ijmr.IJMR_36_1831219096
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–327. doi:10.1016/S1473-3099(17)30753-329276051
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
   Google Scholar
• Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing incidence of extended-spectrum β-lactamase-producing Escherichia coli in community hospitals throughout the Southeastern United States. Infect Control Hosp Epidemiol. 2016;37:49–54. doi:10.1017/ice.2015.23926458226
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62:165.23466435
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
   Google Scholar
• Vallianou N, Dalamaga M, Stratigou T, et al. Do antibiotics cause obesity through long-term alterations in the gut microbiome? A review of current evidence. Curr Obes Rep. 2021:1–19. doi:10.1007/s13679-021-00438-w33400222
   PubMed Web of Science ®Google Scholar
• Anhê FF, Jensen BAH, Varin TV, et al. Type 2 diabetes influences bacterial tissue compartmentalisation in human obesity. Nat Metab. 2020;2(3):233–242. doi:10.1038/s42255-020-0178-932694777
   PubMedGoogle Scholar
• Massier L, Chakaroun R, Tabei S, et al. Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes. Gut. 2020;69(10):1796–1806. doi:10.1136/gutjnl-2019-32011832317332
   PubMed Web of Science ®Google Scholar